Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 63 results for "Tecfidera Treated Patients"

New Data at CMSC Assess Real-World Impact of Rebif® (interfer...

- Data compare Rebif vs. Tecfidera® and Aubagio® in the first year of treatment - Assessments include likelihood of relapse, medical costs and outpatient management resources needs 09:00 ET from EMD Serono ROCKLAND, Mass., June 2, 2016 ... PR Newswire, 4 weeks ago

1 images for "Tecfidera Treated Patients"

European Pharmaceutical Review, 2 months ago
Reuters India

Biogen's MS Drug Fails to Meet Goals in Study

Biogen tumbled 12 percent in Tuesday trading after the biotechnology company said that a multiple sclerosis treatment with the potential to be a blockbuster drug failed to meet key goals in a midstage study. In testing, opicinumab failed to ...
 Bioscience Technology Online3 weeks ago Biogen's MS drug misses main goal in mid-stage study  Yahoo! India3 weeks ago Biogens MS drug misses main goal in mid-stage study  Reuters UK3 weeks ago FDA approves new Biogen multiple sclerosis drug  Boston Globe1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 6, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency2 weeks ago

February 2016 Tecfidera Label Change Adds Information About PML Risks

There seems to have been more Tecfidera progressive multifocal leukoencephalopathy (PML) cases reported in the past year or so. And it seems that lymphonpenia possibly induced by Tecfidera might have a role to play in those additional PML cases. ...
 DrugInjuryLaw.com1 month ago A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice  Drug Injury Watch1 month ago

Real-world data favor dimethyl fumarate, fingolimod for MS

AT THE AAN 2016 ANNUAL MEETING VANCOUVER (FRONTLINE MEDICAL NEWS) Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative ...
 PM 3602 weeks ago

Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026

/PRNewswire/ -- Revenue Forecasts for Leading Submarkets Including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and Also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif MS Drugs - Discover R&D ...
 WorldNetDaily2 weeks ago

5 Attractive Biotechnology Stocks for Healthy Long-term Returns

Home Business News Share the joy Introduction I am a fervent believer that investors are best served by investing towards a specific investment objective that suits their own unique goals, objectives and risk tolerance.
 News EasyBranches.com2 weeks ago 5 Appealing Biotechnology Stocks for Healthy Long-term Returns  Yahoo! Finance2 weeks ago

Amid Plunging Stocks and Failed Trials, Biogen???s CIO Quietly Leaves Company

By Mark Terry , Breaking News Staff With very little fanfare, Biogen ( BIIB )'s chief information officer, Matt Griffiths , left the company after only a year-and-a-half. No reason was given. In May 2015, Biogen announced that ...
 BioSpace2 weeks ago Biogen Loses $8 Billion in Market Value in One Day  Pharma Live3 weeks ago

Annual Report: State of the Bio Industry

The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma's continued ...
 Pharma Live3 weeks ago

Biogen Inc: BIIB Loses $8B on Drug Failure, But Upside Remains

Popular Posts: Recent Posts: How do you make $8 billion vanish in an instant? One way is to develop a multiple sclerosis drug that doesn't work as well as hoped. Just ask Biogen Inc ( BIIB ) investors, who saw the value of BIIB stock slump ...
 InvestorPlace.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less